Phoenix Biotech Acquisition
PBAX | NASDAQ
$5.85
+$0.37 (+6.75%)
At close: Feb 14, 2024, 03:56 PM ET
Phoenix Biotech Acquisition Company Profile
Company profile explainedCompany Profile
Phoenix Biotech Acquisition Corp. currently lacks substantial business operations. The company's primary objective is to complete a strategic business combination, such as a merger, asset acquisition, share exchange, or other form of reorganization, with one or more suitable enterprises. Its focus is on identifying and integrating with a firm engaged in the healthcare or healthcare-related industries within the United States or Europe. This entity was established in 2021 and maintains its headquarters in Oakland, California.
Key Executives
| Name | Position |
|---|---|
| Christopher Ehrlich | Chief Executive Officer & Director |
| Daniel E. Geffken | Chief Financial Officer |
| Douglas Carl Fisher | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 31, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 424B3 | Filing |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 17, 2026 | 424B3 | Filing |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 13, 2026 | 25-NSE | Filing |
| Jun 26, 2026 | 424B3 | Filing |
| Jun 26, 2026 | 8-K | Current Report |
| May 29, 2026 | 424B3 | Filing |
Phoenix Biotech Acquisition
| Country | United States |
| IPO Date | Nov 30, 2021 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Christopher B. Ehrlich |
Stock Details
| Ticker Symbol | PBAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 71902K105 |
| ISIN Number | US71902K1051 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove PBAX